Sign in
Taking people in United StatesPhase 2

Mindfulness sleep program to prevent depression in pregnancy and after birth

Tests a mindfulness sleep program for pregnant women with insomnia to prevent depression.

Key facts

Who runs it
Henry Ford Health System
Where
Novi, United StatesSee the site
Trial code
Registry title
Sleep to Reduce Incident Depression Effectively in Peripartum
Status
Recruiting
Phase
Phase 2
People taking part
500 people, planned
Started
10 Dec 2024
Expected to end
29 Feb 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)
  • Treatment-as-usual (TAU)
Record updated
17 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for pregnant women with insomnia (trouble sleeping) who do not have major depression. It tests an online sleep program to help prevent depression during and after pregnancy.

Age
18 years or older
Sex
Women only
Disease stage
Pregnant with one baby, week 14-31 of pregnancy at screening. Insomnia disorder lasting ≥1 month, Insomnia Severity Index (ISI) score ≥ 11. Edinburgh Postnatal Depression Scale score <13 and no current major depression.
Earlier treatment
Not currently in therapy for major depression or insomnia disorder.

Main reasons for not taking part

  • High-risk pregnancy, such as pre-eclampsia or placenta previa with bleeding (high blood pressure and diabetes are allowed)
  • Active intent to end one's life
  • Night or rotating shift work, or planned travel across 3 or more time zones in the 2 months after screening
  • Untreated restless legs syndrome (RLS), or strong daytime sleepiness (Epworth Sleepiness Scale >15)
  • Uncontrolled sleep or mental disorder, such as narcolepsy, bipolar disorder or epilepsy

This trial only enrols pregnant participants. The registry sentence this rests on: 1. Singleton pregnancy, gestational week 14-31 at screening.

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Singleton pregnancy, gestational week 14-31 at screening
  • DSM-5 Insomnia Disorder (≥1 month duration)
  • Insomnia Severity Index (ISI) score ≥ 11
  • Edinburgh Postnatal Depression Scale score<13 at screening
  • No current DSM-5 Major Depression
  • Reliable internet access for treatment and assessments
  • Not currently engaged in therapy for major depression or insomnia disorder
  • Age 18 years or older

Who cannot take part

  • High risk pregnancy (pre-eclampsia, placenta previa w/ hemorrhage, other conditions deemed serious risk to mother or fetus; hypertension and diabetes are allowed)
  • Uncontrolled sleep or mental disorder inappropriate or unsafe for sleep restriction (narcolepsy, bipolar, epilepsy, etc.)
  • Active suicidal intent
  • Night or rotating shift work, anticipated travel across time 3 or more time zones in the 2 months after baseline screening
  • Untreated RLS (treated RLS is OK)
  • Excessive daytime sleepiness; Epworth Sleepiness Scale>15

Where in United States

  • Henry Ford Medical CenterNovi, United StatesContact: David Kalmbach, PhDTaking people

About the trial

What the trial wants to find out

Perinatal depression (PND) is the most common complication in pregnancy and postpartum, which increases risk for adverse perinatal outcomes such as preterm birth, maternal suicidal thoughts, and impaired mother-infant bonding. Insomnia often precedes PND cases and may serve as an entry point for interventions preventing PND. The proposed project is a large-scale clinical trial to test the effectiveness of a mindfulness-based sleep program designed for pregnant women to improve sleep and alleviate cognitive arousal to reduce risk for PND across pregnancy and postpartum.

The 2 groups in the trial

  • Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)Treatment being tested

    PUMAS is a clinician-administered psychotherapy intervention for prenatal insomnia that includes six weekly 60-minute sessions in an individual format. PUMAS combines behavioral sleep strategies with mindfulness exercises and tailors all components to pregnancy to improve sleep quality. PUMAS will be delivered via telemedicine video.

  • Treatment-as-usual (TAU)Existing treatment, for comparison

    TAU reflects real-world care where patients and their providers make their own treatment decisions for treating prenatal insomnia. Common TAU options include over-the-counter sleep aids, sleep hygiene education, melatonin, and cognitive-behavioral therapy for insomnia. The TAU group will be well-characterized (i.e., the investigators will monitor interventions administered by the usual care providers and collect information on dosage, frequency, duration, adherence) to best describe treatment options sought and completed in the real world.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Sleep to Reduce Incident Depression Effectively in Peripartum
Plain-language title
Mindfulness sleep program to prevent depression in pregnancy and after birthGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
17 April 2026